Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

AMG, CFE, CSM, Telenet, ThromboGenics: Benelux Equity Preview

Aug. 10 (Bloomberg) -- The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.

The AEX-Index in Amsterdam increased 1.3 percent to 287.05. Belgium’s Bel20 Index rose 2.8 percent to 2,154.72. Luxembourg’s LuxX Index lost 0.4 percent to 1,151.01.

Dutch stocks:

AMG Advanced Metallurgical Group NV (AMG NA): The maker of vacuum furnaces and specialty alloys based on aluminum and titanium is scheduled to report second-quarter earnings. AMG shares soared 9.2 percent to 9.35 euros.

CSM NV (CSM NA): The world’s biggest maker of bakery ingredients may say first-half net income dropped to 31.1 million euros ($44.2 million), according to the average of three analyst estimates compiled by Bloomberg, from 54.2 million euros a year earlier. CSM shares advanced 2.8 percent to 15.99 euros.

Belgian stocks:

Ackermans & van Haaren NV (ACKB BB), Cie. d’Entreprises CFE SA (CFEB BB): Dredging Environmental & Marine Engineering NV, the dredging company co-owned by Ackermans and CFE, said its Australian joint venture with Van Oord Groep NV won a contract valued at A$120 million ($122 million) for the development of the Gladstone liquefied-natural-gas project. Ackermans shares gained 4 percent to 53.09 euros. CFE shares climbed 5.8 percent to 38.45 euros.

Telenet Group Holding NV (TNET BB): The Belgian cable operator controlled by Liberty Global Inc. said it initiated a stock buyback program and will give weekly updates of the shares bought back to cover stock option awards to management. Telenet shares increased 7.3 percent to 26.39 euros.

ThromboGenics NV (THR BB): The Belgian developer of the Ocriplasmin eye-disease treatment said it plans to seek European regulatory approval for the experimental drug in the next two months, with a U.S. filing scheduled before year-end. The shares surged 9.7 percent to 14.53 euros.

To contact the reporters on this story: John Martens in Brussels at jmartens1@bloomberg.net; Fred Pals in Amsterdam at fpals@bloomberg.net

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.